New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export SCTX’s income statement to Excel — free account
Scribe Therapeutics Inc.
SCTXScribe Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $51.2 million.
12.07
1.15
−8.70%
After hours trading: 12.00, down 0.58%, last trade Fri 7:39pm Eastern.
Follow SCTX
Alert me
Scribe Therapeutics Inc. (SCTX) news
Stories the last two months, newest first
More headlines
- Cathie Wood Trims EV Stock and Makes a Move on Driverless Trucks GuruFocus
- Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences GlobeNewswire
- Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought The Motley Fool
- Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
- Scribe Therapeutics to Participate in Upcoming Investor Conferences
- Scribe’s Genetic Editing Aims to Prevent Heart Attacks
- Scribe Therapeutics Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares, and Closing of the Concurrent Private Placement
- Scribe Therapeutics Soars 67% After $128.7 Million Upsized IPO
- Scribe Therapeutics Announces Pricing of Upsized Initial Public Offering